Evidence map›Paper›PMID 38235133›Full record

ReviewFrontiers in immunology2023

Noval advance of histone modification in inflammatory skin diseases and related treatment methods.

Lichen Zhang, Rongrong Chai, Zongguang Tai, Fengze Miao, Xinwei Shi, Zhongjian Chen, Quangang Zhu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lichen Zhang *Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Rongrong Chai *Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Zongguang TaiShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Fengze MiaoShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Xinwei ShiShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhongjian ChenShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Quangang ZhuShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai Skin Disease Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory skin diseases are a group of diseases caused by the disruption of skin tissue due to immune system disorders. Histone modification plays a pivotal role in the pathogenesis and treatment of chronic inflammatory skin diseases, encompassing a wide range of conditions, including psoriasis, atopic dermatitis, lupus, systemic sclerosis, contact dermatitis, lichen planus, and alopecia areata. Analyzing histone modification as a significant epigenetic regulatory approach holds great promise for advancing our understanding and managing these complex disorders. Additionally, therapeutic interventions targeting histone modifications have emerged as promising strategies for effectively managing inflammatory skin disorders. This comprehensive review provides an overview of the diverse types of histone modification. We discuss the intricate association between histone modification and prevalent chronic inflammatory skin diseases. We also review current and potential therapeutic approaches that revolve around modulating histone modifications. Finally, we investigated the prospects of research on histone modifications in the context of chronic inflammatory skin diseases, paving the way for innovative therapeutic interventions and improved patient outcomes.

Indexed as

Dermatitis, AtopicPsoriasisSkin DiseasesHistone CodeHistonesHumansHistonesepigenetichistone modificationinflammatory reactioninflammatory skin diseasetherapy

Identifiers

PMID38235133
PMCPMC10792063
OpenAlexW4390570450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.